Product Information
SUMATRIPTAN 20 MG NASAL SPRAY is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $16.5061 per EA under NDC 45802059806. Its NADAC has been published 304 times since Dec 9, 2020.
FDA first approved this application on Sep 21, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802059806
Classification
Generic
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTANApproval Type
Generic (ANDA)
FDA Application
ANDA213465FDA Approved
9/21/2020
TE Code
AB
On Market Since
10/4/2020
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 20 MG NASAL SPRAY has been published 304 times since Dec 9, 2020, and over the history we have for it it has declined 61.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.5061 per EA |
|---|---|
| All-time high | $45.7134 (Jan 13, 2021) |
| All-time low | $13.8657 (Nov 20, 2024) |
| 52-week high | $17.6932 |
| 52-week low | $15.8842 |
| Median price | $19.4090 |
| Average price | $22.4562 |
| Largest weekly change | -38.3% (Nov 20, 2024) |
| Weeks tracked | 304 |
| Tracking since | Dec 9, 2020 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 20 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 20 MG NASAL SPRAY, manufactured by Padagis Israel Pharmaceuticals Ltd, is $16.5061 per EA (NDC 45802059806), effective Sep 30, 2026.
How has the price of SUMATRIPTAN 20 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 20 MG NASAL SPRAY has declined 61.9%. It has been tracked across 304 weekly CMS publications since Dec 9, 2020.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 20 MG NASAL SPRAY?
Since Dec 9, 2020, the NADAC for SUMATRIPTAN 20 MG NASAL SPRAY has ranged from a low of $13.8657 (Nov 20, 2024) to a high of $45.7134 (Jan 13, 2021), with a median of $19.4090 per EA.
Are there cheaper alternatives to SUMATRIPTAN 20 MG NASAL SPRAY?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUMATRIPTAN 20 MG NASAL SPRAY, is $15.9964 per EA — about 3% below SUMATRIPTAN 20 MG NASAL SPRAY.
Who manufactures SUMATRIPTAN 20 MG NASAL SPRAY?
SUMATRIPTAN 20 MG NASAL SPRAY (NDC 45802059806) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.